The debate over QALYs in US drug value assessments continues

In response to the Protecting Health Care for All Patients Act introduced into US legislation earlier this month that would prohibit federal agencies from using quality-adjusted life years (QALYs) in drug value assessments, many stakeholders have voiced their views on the highly polarized topic. In a new opinion article published in STAT, Joshua Cohen, Peter Neumann and Daniel Ollendorf of the Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center have voiced their views on the ongoing debate surrounding the use of QALYs in drug value assessments. Providing the ‘for’ perspective, the authors assert...